Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Indo-Bangla Pharmaceuticals Ltd (INDO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
13.30 -0.20    -1.48%
02/05 - Closed. Currency in BDT ( Disclaimer )
  • Volume: 506,761
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 13.10 - 13.50
Type:  Equity
Market:  Bangladesh
ISIN:  BD0494IBPL08 
S/N:  IBP
Indo-Bangla Pharmaceuticals 13.30 -0.20 -1.48%

DH:INDO Financials

 
This summary provides an overview of the most significant critical numbers from each of the Indo-Bangla Pharmaceuticals Ltd financial reports, including theIndo-Bangla Pharmaceuticals Ltd income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the DH:INDO financials over time via breakdowns of their annual reports.

Indo-Bangla Pharmaceuticals Limited reported earnings results for the first quarter ended September 30, 2023. For the first quarter, the company reported sales was BDT 85.3 million compared to BDT 121.49 million a year ago. Net income was BDT 0.99068 million compared to BDT 19.87 million a year ago. Basic earnings per share from continuing operations was BDT 0.01 compared to BDT 0.17 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

INDO Income Statement & Profits

Gross margin TTM 18.23%
Operating margin TTM 3.33%
Net Profit margin TTM -2.71%
Return on Investment TTM 0.46%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 58.05 85.3 49.15 103.39
Gross Profit 6.82 14.94 6.46 25.72
Operating Income -2.47 5.11 0.367 6.85
Net Income -6.56 0.991 -3.47 1.01

INDO Balance Sheet

Quick Ratio MRQ 2.08
Current Ratio MRQ 4.55
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 2%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 1868.33 1878.71 1875.77 1921.99
Total Liabilities 252.08 255.89 253.95 296.7
Total Equity 1616.25 1622.81 1621.82 1625.29

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM 0.8
Revenue/Share TTM 2.55
Operating Cash Flow  13.25%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 15.59 10.62 66.06 1.16
Cash From Investing Activities -2.57 -4.57 -19.48 0
Cash From Financing Activities -11.56 -2.46 -47.24 -8.32
Net Change in Cash 1.46 3.6 -0.657 -7.16
* In Millions of BDT (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

INDO Price Commentary

Write your thoughts about Indo-Bangla Pharmaceuticals Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Al Kayes
Al Kayes Oct 24, 2019 3:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thu, 2nd May 20199:51 amQ3 Financials(Q3 Un-audited): EPS was Tk. 0.43 for January-March 2019 as against Tk. 0.35 for January-March 2018; EPS was Tk. 1.13 for July 2018-March 2019 as against Tk. 1.02 for July 2017-March 2018. NOCFPS was Tk. 0.98 for July 2018-March 2019 as against Tk. 0.74 for July 2017-March 2018. NAV per share was Tk. 13.16 as on March 31, 2019 and Tk. 14.19 as on June 30, 2018.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email